DEXCOM INC. - 10-Q Filing Summary (Q2 2025)
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. DexCom, Inc. is a medical device company focused on continuous glucose monitoring (CGM) systems. The company operates as a single reportable segment, deriving revenue primarily from disposable sensors and reusable hardware. Key product milestones include the launch of the Stelo biosensor in August 2024 and FDA clearance for the Dexcom G7 15-Day system in April 2025.
Key Financial Metrics
| Metric | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Revenue | $1,157.1M | $1,004.3M | $2,193.1M | $1,925.3M |
| Gross Profit | $688.8M | $626.7M | $1,277.8M | $1,188.6M |
| Gross Margin | 59.5% | 62.4% | 58.3% | 61.7% |
| Operating Income | $212.6M | $158.0M | $346.3M | $259.1M |
| Net Income | $179.8M | $143.5M | $285.2M | $289.9M |
| Diluted EPS | $0.45 | $0.35 | $0.71 | $0.71 |
| Operating Cash Flow (YTD) | $486.8M | $488.6M | - | - |
| Cash & Equivalents (End of Period) | $1,159.0M | - | - | - |
| Total Liquidity (Cash + Short-term Securities) | $2,929.3M | - | - | - |
Debt: Total principal amount of senior convertible notes is $2,457.5M ($1,207.5M due 2025; $1,250.0M due 2028). No borrowings under the $200M credit facility.
Material Changes vs. Prior Period
- Revenue Growth: Q2 revenue increased 15% year-over-year, driven by a 15% increase in U.S. sales and 16% in International sales. Growth was fueled by increased sales volume of disposable sensors and the addition of approximately 500,000–600,000 net customers in 2024.
- Margin Compression: Gross margin decreased from 62.4% to 59.5% in Q2. Management attributed this to inefficiencies in ensuring supply availability, build configurations lowering production yield, and product/channel mix changes.
- Expense Management: Selling, general, and administrative (SG&A) expenses decreased by 1% in Q2, primarily due to a $22.9M reduction in legal expenses following the settlement of a patent infringement lawsuit in December 2024.
- Inventory Charges: The company recorded $8.8M in excess and obsolete inventory charges in Q2 2025, compared to $0.1M in Q2 2024.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue generating positive cash flows. The company anticipates significant capital expenditures in the coming year for manufacturing facility build-outs (specifically in Ireland) and equipment.
- Share Repurchase: In April 2025, the Board authorized a $750M share repurchase program. No repurchases were made in the first half of 2025.
- Regulatory Risk (FDA Warning Letter): In March 2025, DexCom received an FDA warning letter regarding deficiencies in manufacturing processes and quality management systems at facilities in San Diego and Mesa. While the letter does not currently restrict production or sales, failure to resolve these issues could lead to recalls, production shutdowns, or other enforcement actions.
- Legal Proceedings: The company is defending against a consolidated securities class action lawsuit alleging false statements regarding 2024 revenue expectations. A motion to dismiss the amended complaint was filed in June 2025.
- Tax Legislation: The company is assessing the impact of the "One Big Beautiful Bill Act" signed into law on July 4, 2025.
Investor Verification Checklist
- FDA Resolution: Verify the status of the corrective action plan submitted in response to the March 2025 FDA warning letter and any potential impact on production capacity.
- Margin Trajectory: Monitor future quarters to determine if gross margin compression is a temporary supply-chain issue or a structural shift due to pricing headwinds and rebate eligibility.
- Debt Maturity: Confirm the company's strategy for the $1.21B senior convertible notes maturing in November 2025 (refinancing, conversion, or cash repayment).
- Legal Exposure: Track the outcome of the pending motion to dismiss in the securities class action litigation.
- Stelo Adoption: Assess the contribution of the over-the-counter Stelo product to revenue growth, as it is excluded from the primary customer count cited in the report.